Who is sponsoring NCT01898273?

NCT01898273 is sponsored by Cellectar Biosciences, Inc..

What condition does NCT01898273 study?

NCT01898273 studies Glioblastoma.

What is the status of NCT01898273?

NCT01898273 is currently TERMINATED.

Last reviewed 2015-09-08 · How we verify

Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma

NCT01898273 Phase 2 TERMINATED

The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.

Details

Lead sponsor	Cellectar Biosciences, Inc.
Phase	Phase 2
Status	TERMINATED
Enrolment	7
Start date	2014-02
Completion	2015-12

Conditions

Glioblastoma

Interventions

I-124-CLR1404

Primary outcomes

Optimal Imaging Parameters - Dose — 8 days
Up to two dose levels (5 mCi and 7.5 mCi) will be evaluated in conjunction with multiple imaging time points to determine the optimal parameters for PET/CT brain imaging. Dosing will begin at 5 mCi and if the images are deemed inadequate, as assessed by count statistics and image quality, the 7.5 mCi dose level will be evaluated.

Countries

United States